Andrea Forschner1, Felizitas Eichner2,3, Teresa Amaral2,4, Ulrike Keim2, Claus Garbe2, Thomas Kurt Eigentler2. 1. Department of Dermatology, University Medical Center Tübingen, Liebermeisterstr. 25, 72076, Tübingen, Germany. andrea.forschner@med.uni-tuebingen.de. 2. Department of Dermatology, University Medical Center Tübingen, Liebermeisterstr. 25, 72076, Tübingen, Germany. 3. Graduate School of Life Sciences, Utrecht University, Utrecht, Netherlands. 4. Portuguese Air Force Health Direction, Paço do Lumiar, 1649-020, Lisbon, Portugal.
Abstract
BACKGROUND: During 2011 and 2014, new treatment modalities like tyrosine kinase inhibitors and checkpoint inhibitors were introduced into the therapy of metastatic melanoma. This study addresses the question whether overall survival (OS) of metastatic melanoma patients has already been improved in 441 patients diagnosed with metastatic melanoma between 2011 and 2014 in the real-world setting at the University Hospital Tuebingen. METHODS: All patients were documented with their different therapies by the CMMR and followed up until March 2016. Survival probabilities were calculated by Kaplan-Meier estimators, and log-rank tests were used to evaluate significances. Hazard ratios were estimated by Cox regression analysis for survival probabilities and prognostic factors in stage IV melanoma. RESULTS: Best OS was observed in patients (n = 93) treated by metastasectomy as primary treatment with the intention to completely excise all metastases (3-year OS 61%). OS for patients with first-line systemic treatment (n = 258) was unfavorable in general (3-year OS 23%). Of those, the most favorable outcome was observed in patients without brain metastasis and treated with immunotherapy (mostly ipilimumab), as first-line treatment (median OS 35 months, 3-year OS 43%). In case of brain metastases, patients with targeted therapy had a better OS (median 14 months) than patients with ipilimumab treatment (median 7 months). Among all patients with first-line systemic treatment, outcome of patients diagnosed in the years 2013/2014, compared to 2011 and 2012, showed an improved survival. Three-year OS for patients that entered stage IV in 2013/2014 was 37% compared to those that entered stage IV in 2011 (18%) and 2012 (20%). CONCLUSION: The analysis of real-world data of treatment of metastatic melanoma showed an improvement of OS with both immunotherapy and targeted therapy. In case of cerebral metastasis, patients treated with targeted therapy showed a longer median OS than patients treated with ipilimumab.
BACKGROUND: During 2011 and 2014, new treatment modalities like tyrosine kinase inhibitors and checkpoint inhibitors were introduced into the therapy of metastatic melanoma. This study addresses the question whether overall survival (OS) of metastatic melanomapatients has already been improved in 441 patients diagnosed with metastatic melanoma between 2011 and 2014 in the real-world setting at the University Hospital Tuebingen. METHODS: All patients were documented with their different therapies by the CMMR and followed up until March 2016. Survival probabilities were calculated by Kaplan-Meier estimators, and log-rank tests were used to evaluate significances. Hazard ratios were estimated by Cox regression analysis for survival probabilities and prognostic factors in stage IV melanoma. RESULTS: Best OS was observed in patients (n = 93) treated by metastasectomy as primary treatment with the intention to completely excise all metastases (3-year OS 61%). OS for patients with first-line systemic treatment (n = 258) was unfavorable in general (3-year OS 23%). Of those, the most favorable outcome was observed in patients without brain metastasis and treated with immunotherapy (mostly ipilimumab), as first-line treatment (median OS 35 months, 3-year OS 43%). In case of brain metastases, patients with targeted therapy had a better OS (median 14 months) than patients with ipilimumab treatment (median 7 months). Among all patients with first-line systemic treatment, outcome of patients diagnosed in the years 2013/2014, compared to 2011 and 2012, showed an improved survival. Three-year OS for patients that entered stage IV in 2013/2014 was 37% compared to those that entered stage IV in 2011 (18%) and 2012 (20%). CONCLUSION: The analysis of real-world data of treatment of metastatic melanoma showed an improvement of OS with both immunotherapy and targeted therapy. In case of cerebral metastasis, patients treated with targeted therapy showed a longer median OS than patients treated with ipilimumab.
Authors: Annette Pflugfelder; Corinna Kochs; Andreas Blum; Marcus Capellaro; Christina Czeschik; Therese Dettenborn; Dorothee Dill; Edgar Dippel; Thomas Eigentler; Petra Feyer; Markus Follmann; Bernhard Frerich; Maria-Katharina Ganten; Jan Gärtner; Ralf Gutzmer; Jessica Hassel; Axel Hauschild; Peter Hohenberger; Jutta Hübner; Martin Kaatz; Ulrich R Kleeberg; Oliver Kölbl; Rolf-Dieter Kortmann; Albrecht Krause-Bergmann; Peter Kurschat; Ulrike Leiter; Hartmut Link; Carmen Loquai; Christoph Löser; Andreas Mackensen; Friedegund Meier; Peter Mohr; Matthias Möhrle; Dorothee Nashan; Sven Reske; Christian Rose; Christian Sander; Imke Satzger; Meinhard Schiller; Heinz-Peter Schlemmer; Gerhard Strittmatter; Cord Sunderkötter; Lothar Swoboda; Uwe Trefzer; Raymond Voltz; Dirk Vordermark; Michael Weichenthal; Andreas Werner; Simone Wesselmann; Ansgar J Weyergraf; Wolfgang Wick; Claus Garbe; Dirk Schadendorf Journal: J Dtsch Dermatol Ges Date: 2013-08 Impact factor: 5.584
Authors: Georgina V Long; Daniil Stroyakovskiy; Helen Gogas; Evgeny Levchenko; Filippo de Braud; James Larkin; Claus Garbe; Thomas Jouary; Axel Hauschild; Jean-Jacques Grob; Vanna Chiarion-Sileni; Celeste Lebbe; Mario Mandalà; Michael Millward; Ana Arance; Igor Bondarenko; John B A G Haanen; Johan Hansson; Jochen Utikal; Virginia Ferraresi; Nadezhda Kovalenko; Peter Mohr; Volodymr Probachai; Dirk Schadendorf; Paul Nathan; Caroline Robert; Antoni Ribas; Douglas J DeMarini; Jhangir G Irani; Suzanne Swann; Jeffrey J Legos; Fan Jin; Bijoyesh Mookerjee; Keith Flaherty Journal: Lancet Date: 2015-05-31 Impact factor: 79.321
Authors: Caroline Robert; Jacob Schachter; Georgina V Long; Ana Arance; Jean Jacques Grob; Laurent Mortier; Adil Daud; Matteo S Carlino; Catriona McNeil; Michal Lotem; James Larkin; Paul Lorigan; Bart Neyns; Christian U Blank; Omid Hamid; Christine Mateus; Ronnie Shapira-Frommer; Michele Kosh; Honghong Zhou; Nageatte Ibrahim; Scot Ebbinghaus; Antoni Ribas Journal: N Engl J Med Date: 2015-04-19 Impact factor: 91.245
Authors: John A Thompson; Omid Hamid; David Minor; Asim Amin; Ilan G Ron; Ruggero Ridolfi; Hazem Assi; David Berman; Jonathan Siegel; Jeffrey S Weber Journal: J Immunother Date: 2012-01 Impact factor: 4.456
Authors: Charles M Balch; Jeffrey E Gershenwald; Seng-Jaw Soong; John F Thompson; Michael B Atkins; David R Byrd; Antonio C Buzaid; Alistair J Cochran; Daniel G Coit; Shouluan Ding; Alexander M Eggermont; Keith T Flaherty; Phyllis A Gimotty; John M Kirkwood; Kelly M McMasters; Martin C Mihm; Donald L Morton; Merrick I Ross; Arthur J Sober; Vernon K Sondak Journal: J Clin Oncol Date: 2009-11-16 Impact factor: 44.544
Authors: Annette Pflugfelder; Thomas K Eigentler; Ulrike Keim; Benjamin Weide; Ulrike Leiter; Kristian Ikenberg; Mark Berneburg; Claus Garbe Journal: PLoS One Date: 2011-02-16 Impact factor: 3.240
Authors: Andrea Forschner; Susann-Cathrin Olthof; Brigitte Gückel; Peter Martus; Werner Vach; Christian la Fougère; Konstantin Nikolaou; Ulrike Keim; Thomas Kurt Eigentler; Claus Garbe; Christina Pfannenberg Journal: Eur J Nucl Med Mol Imaging Date: 2017-03-18 Impact factor: 9.236
Authors: Clemens Krepler; Katrin Sproesser; Patricia Brafford; Marilda Beqiri; Bradley Garman; Min Xiao; Batool Shannan; Andrea Watters; Michela Perego; Gao Zhang; Adina Vultur; Xiangfan Yin; Qin Liu; Ioannis N Anastopoulos; Bradley Wubbenhorst; Melissa A Wilson; Wei Xu; Giorgos Karakousis; Michael Feldman; Xiaowei Xu; Ravi Amaravadi; Tara C Gangadhar; David E Elder; Lauren E Haydu; Jennifer A Wargo; Michael A Davies; Yiling Lu; Gordon B Mills; Dennie T Frederick; Michal Barzily-Rokni; Keith T Flaherty; Dave S Hoon; Michael Guarino; Joseph J Bennett; Randall W Ryan; Nicholas J Petrelli; Carol L Shields; Mizue Terai; Takami Sato; Andrew E Aplin; Alexander Roesch; David Darr; Steve Angus; Rakesh Kumar; Ensar Halilovic; Giordano Caponigro; Sebastien Jeay; Jens Wuerthner; Annette Walter; Matthias Ocker; Matthew B Boxer; Lynn Schuchter; Katherine L Nathanson; Meenhard Herlyn Journal: Cell Rep Date: 2017-11-14 Impact factor: 9.423
Authors: Marta Polkowska; Paweł Ekk-Cierniakowski; Edyta Czepielewska; Wojciech Wysoczański; Wojciech Matusewicz; Małgorzata Kozłowska-Wojciechowska Journal: J Cancer Res Clin Oncol Date: 2017-06-12 Impact factor: 4.553
Authors: Joanna Mangana; Phil F Cheng; Corina Kaufmann; Valerie C Amann; Anna L Frauchiger; Viola Stögner; Ulrike Held; Roger von Moos; Olivier Michielin; Ralph P Braun; Mitchell P Levesque; Simone M Goldinger; Reinhard Dummer Journal: Melanoma Res Date: 2017-08 Impact factor: 3.599
Authors: Tanja Zitzelsberger; Thomas K Eigentler; Patrick Krumm; Konstantin Nikolaou; Claus Garbe; Meinrad Gawaz; Bernhard Klumpp Journal: Cancer Imaging Date: 2017-07-01 Impact factor: 3.909
Authors: Tobias Sinnberg; Mitchell P Levesque; Jelena Krochmann; Phil F Cheng; Kristian Ikenberg; Francisco Meraz-Torres; Heike Niessner; Claus Garbe; Christian Busch Journal: Mol Cancer Date: 2018-02-17 Impact factor: 27.401